Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Conditions
B-cell Acute Lymphoblastic Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
University of Colorado - Aurora Cancer Center, Aurora, Colorado, United States
Sarah Cannon - Colorado Blood Cancer Institute, Denver, Colorado, United States
University of Chicago, Chicago, Illinois, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
Weill Medical College of Cornell University, New York, New York, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Sarah Cannon - HCA Research Institute, Nashville, Tennessee, United States
Sarah Cannon - St. David's South Austin Medical Center, Austin, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio, Texas, United States
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
CHU de Nantes - Hôtel-Dieu, Nantes, France
Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes Département d'Hématologie, Paris, France
Hôpital Robert Debré - Service d'hémato-immunologie, Paris, France
Hôpital Lyon Sud, Pierre-Bénite, France
CHU Rennes - Hopital Pontchaillou, Rennes, France
Study leads
Nitin Jain, MD
Principal Investigator
M.D. Anderson Cancer Center